Since 2016, JDRF and Sernova Corp., a clinical-stage regenerative medicine company, have been collaborating on innovative technology to treat hypoglycaemia (low sugar) unawareness in patients with severe T1D.
JDRF is excited to be launching our new Access for All campaign this week to urge provincial and territorial governments, insurers and employers to help make life-changing technologies affordable and accessible for Canadians with type 1 diabetes.
Currently, JDRF-funded researcher, Dr. Jan Dutz, and his team at the University of British Columbia are investigating whether the administration of an antibody called ustekinumab among adults and children newly diagnosed with T1D can protect insulin-producing beta cells.
Currently, JDRF-funded researcher, Dr. Jan Dutz, and his team at the University of British Columbia are investigating whether the administration of an antibody called ustekinumab among adults and children newly diagnosed with T1D can protect insulin-producing beta cells.
New technologies for people with type 1 diabetes (T1D) can significantly improve quality of life, but only a limited number of individuals have access to them.
As the incidence of type 1 diabetes (T1D) continues to grow, Canadians have long speculated whether environmental factors – namely pollution – could be responsible for triggering an autoimmune attack.
While the winter season can be a fun time filled with skiing, sledding and mugs of steaming cocoa, it can also be marked by not-so-fun events like the flu, sick days and visits to the clinic.
In April, 10-year-old Grace Bull boarded a plane in Vancouver with her parents, David Bull and JoAnne Strongman, on the way to Palm Desert in California. She was planning to spend her spring break relaxing by the pool and soaking up the sun. She had no idea that when she arrived back home, her life would never be the same.
Dr. Rémi Rabasa-Lhoret, a JDRF-funded endocrinologist at the Institut de recherches cliniques de Montréal best known for his work on the artificial pancreas, is collaborating on the development of a province-wide registry of people with T1D in Quebec.
Thanks to a grant from JDRF, Rice University (TX) bioengineers, Drs. Omid Veiseh and Jordan Miller are combining cell-based therapy applications with sophisticated 3D-printed technologies to help the cells continue to flourish and produce insulin.
While frequent meetings with a health care provider result in better glucose control, it is often hard for individuals and families to commit to the traditional health care’s rigorous schedules and long waiting lists.
As someone directly touched by type 1 diabetes, I hope you will join me on this journey as we continue to invest in the advancement of T1D research.
